Neurology devices are used to diagnose, prevent, and treat various neurological disorders such as Alzheimer’s, spinal cord injury, and traumatic brain injury. These devices are also used to restore hearing and sight for patients with limb loss or congenital limb differences. The main types of neurology devices are cerebrospinal fluid management (CSF) devices and equipment, interventional neurology devices and equipment, neurosurgery devices and equipment, and neurostimulation devices. The neurostimulation device is a device that generates the electrical impulses placed under the skin of specific parts of the patient's body. The type of expenditures is public and private. The products included are instruments/equipment and disposables. The various end-users involved are hospitals and clinics, diagnostic laboratories, and others. The neurology devices market research report is one of a series of new reports from The Business Research Company that provides neurology devices market statistics, including neurology devices industry global market size, regional shares, competitors with a neurology devices market share, detailed neurology devices market segments, market trends and opportunities, and any further data you may need to thrive in the neurology devices industry. This neurology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global neurology devices market grew from $15.89 billion in 2022 to $17.67 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurology devices market is expected to grow to $26.08 billion in 2027 at a CAGR of 10.2%. The increase in the patient pool due to the rising geriatric population globally contributed significantly to the growth of the neurology devices market during the historic period. According to the World Health Organization, the number of people aged 60 years and above was 1 billion in 2020 and the number will rise to 1.4 billion by 2030 and it will reach 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove healthcare expenditure. These factors increased the demand for neurology devices and drove the market during the historic period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These regulations include changes to equipment approval procedures and others. For instance, the United States Food and Drug Administration is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the market. Neurology device manufacturers are investing in the research and development of implantable wireless brain devices to treat neurological and psychiatric diseases. The neuromodulation devices are tiny devices with a wireless neuromodulator, implanted inside the cranium (skull) to communicate with the brain and stimulate nerves in the body. They are equipped with antennas, application-specific integrated circuits, ceramic lid, and feedthrough. These devices are used for relieving depression, traumatic brain injury, stress, and bipolar disorders by manipulating brain signals accordingly. For instance, in August 2020, leading global medical technology player Medtronic rolled out a plan to expand its Hyderabad research and development (R&D) center into its second-largest research hub in five years. The company is investing Rs 1,200 crore for the purpose. The investment planned for five years will see its employee strength go up from the existing 350 to about 1,000. The MEIC will be providing software and engineering services across four key verticals - cardiac, neuro, renal, and minimally invasive surgery of the company. Major companies in the neurology devices market include Medtronic Inc., Stryker Corporation, Terumo Corporation, Integra Lifesciences, Boston Scientific Corporation, Penumbra, Inc., B. Braun Group, Nevro, LivaNova, PLC, and Natus Medical. North America was the largest region in the global neurology devices market in 2022. Asia-Pacific was the second largest region in the global neurology devices market. Africa. was the smallest region in the global neurology devices market. The regions covered in the neurology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the neurology devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The neurology devices market consists of sales of neuro thrombectomy devices, carotid artery stents, embolic coils, and support devices that are used to treat neurological disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global neurology devices market is segmented - 1) By Type: Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables Subsegments Covered: CSF Drainage Systems, CSF Shunts, Aneurysm Coiling & Embolization Devices, Neurothrombectomy Devices, Angioplasty Devices, Interventional Neurology Support Devices, Neurosurgical Navigation Systems, Neurosurgical endoscopes, Aneurysm Clips, Stereotactic Systems, Other Neurosurgery Devices, Implantable Neurostimulation Devices, External Neurostimulation Devices

Neurosurgery devices and equipment are used to perform neurosurgical procedures that are concerned with the diagnosis, prevention, and treatment of disorders affecting any portion of the nervous system. The main device types of neurosurgery devices and equipment are the neuroendoscope, stereotactic systems, aneurysm clips, neurostimulation devices, cerebrospinal fluid management devices, neurosurgical evacuation devices, neurosurgical navigation systems, neurosurgery surgical power tools, and others (ultrasonic aspirators, surgical instruments). The neuroendoscope is a device that allows neurosurgeons to perform less invasive procedures and surgical approaches in a manner that minimizes disruption to surrounding tissues. The surgery types are intracranial surgery, endonasal neurosurgery, and spinal surgery. The various end-users are hospitals and ambulatory surgical centres. The neurosurgery devices and equipment market research report is one of a series of new reports from The Business Research Company that provides neurosurgery devices and equipment market statistics, including neurosurgery devices and equipment industry global market size, regional shares, competitors with a neurosurgery devices and equipment market share, detailed neurosurgery devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the neurosurgery devices and equipment industry. This neurosurgery devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global neurosurgery devices and equipment market size will grow from $7.17 billion in 2022 to $8.12 billion in 2023 at a compound annual growth rate (CAGR) of 13.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurosurgery devices and equipment market size is expected to grow to $12.93 billion in 2027 at a CAGR of 12.3%. The rise in neurological disorders is driving the neurosurgery devices market. A neurological disorder is caused due to the effect on the nervous system which includes the spinal cord, and brain. These disorders include epilepsy and Alzheimer's. According to an article on US Pharmacist, out of the most common neurological disorders, stroke accounts for 51.3%, Alzheimer’s disease 21.4%, Epilepsy 11.6%, traumatic brain injury 6.8%, Parkinson’s disease 4.7%, and brain tumor 2.8%. Furthermore, 1.2 million people are frequently diagnosed with adult-onset brain disorders. An increase in these disorders is driving the growth of the neurosurgery devices and equipment market. According to the Alzheimers Association, millions of Americans have Alzheimer’s or other dementias. As the size and proportion of the U.S. population age 65 and older continue to increase, the number of Americans with Alzheimer’s will grow from 6.2 million in 2021 to 13.8 million by 2060. The stringent US FDA approval process is restraining the Neurosurgery devices market. US FDA takes around 6 months to approve the premarket submissions to demonstrate the device and check if the device is safe and effective. Most of the neurosurgery devices should get premarket approval from the FDA before entering into the market. For example, In the US, only 2,800 (31%) medical devices have cleared the FDA premarket submissions, and the remaining 69% are rejected. However, the technical sections’ assessment is done simultaneously and therefore the manufacturers should identify the time taking steps and plan the work accordingly and plan an estimated date of approval. Also, the license validity and renewal of the application take a toll on the manufacturer and add to the existing regulatory burden. Therefore, the manufacturers of neurosurgical devices should plan well and communicate effectively to minimize the costs and reduce timelines. Minimally invasive surgical procedures and approaches are the new frontiers in neurosurgery as they result in less pain than open surgeries, shorter recovery times, less scarring, increase surgeon mobility and reduce equipment costs. Neuroendoscopy is a minimally invasive neurosurgical procedure performed through neurosurgery devices to correct hydrocephalus, remove tumors, treat vascular disease, and manage other disorders. Neurosurgery device manufacturers are innovating and integrating technologies for advanced endoscope-assisted neurosurgery to provide efficient minimally invasive surgeries, operative procedures, clinical advances, and new technological developments. For instance, end-users such as hospitals, ambulatory surgical centres, and others are using smartphones with endoscopes for performing safe and efficient endoscope-assisted neurosurgery. In New York-Presbyterian Hospital/Columbia University Medical Center, minimally invasive neurosurgeries are preferred over open surgeries with the help of specialized instruments and technologies such as a camera-assisted endoscope, high-powered operating microscope, computer-assisted navigation system, and others to treat conditions in adults and children. The European Commission adopted two new regulations for medical devices to enhance safety, take effective measures in the event of concerns, and improve traceability. These regulations provide the medical device manufacturers with a stronger mandate for assessment of medical devices by independent notified bodies, a unique identification number for improving traceability throughout the supply chain, availability of clinical data on devices, and provides a central database to provide patients, healthcare professionals and the public with comprehensive information on products. These rules help manufacturers to meet the standards, safety requirements and to make better-informed decisions. Major players in the neurosurgery devices and equipment market are Medtronic, Boston Scientific Corporation, Stryker, Conmed Corporation, Smith & Nephew, Integra LifeSciences, Olympus Corporation, NICo., Karl Storz GmbH & Co. KG, and Richard Wolf GmbH. North America was the largest region in the global neurosurgery devices and equipment market in 2022. Asia-Pacific was the second-largest region in the neurosurgery devices and equipment market. The regions covered in the global neurosurgery devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurosurgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The neurosurgery devices and equipment market consists of sales of neurostimulation devices, neuroendoscope, cerebrospinal fluid management devices, neurosurgical evacuation device, neurosurgery surgical power tools, ultrasonic aspirators, and surgical instruments. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global neurosurgery devices and equipment market is segmented - 1) By Device Type: Neuroendoscope, Stereotactic Systems, Aneurysm Clips, Neurostimulation Devices, Cerebrospinal Fluid Management Devices, Neurosurgical Evacuation Device, Neurosurgical Navigation Systems, Neurosurgery Surgical Power Tools, Others(Ultrasonic Aspirators, Surgical Instruments) 2) By Surgery Type: Intracranial Surgery, Endonasal Neurosurgery, Spinal Surgery 3) By End User: Hospitals, Ambulatory Surgical Centers

Neurostimulation devices are implantable and programmable medical devices that send low voltage electricity to a specific nerve or target in the spinal cord or brain to affect neuronal transmissions. This procedure is used to treat or modulate motor functions in conditions such as neuropathic pain, chronic pain, major treatment-resistant depression Parkinson’s disease, epilepsy, incontinence, gastroparesis, and essential tremor. The main products of the neurostimulation devices are implantable devices and external devices. The implantable devices involved are cochlear implants, deep brain stimulation; spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation, and gastric electric stimulation and the external devices are transcranial magnetic stimulation (TMS) and transcutaneous electrical nerve stimulation (TENS). The various applications of implantable devices are pain management, epilepsy, essential tremor, urinary and fecal incontinence, depression, dystonia, gastroparesis, and Parkinson's disease that are used by various end-users such as hospitals, rehabilitation centres, and medical clinics. The neurostimulation device market research report is one of a series of new reports from The Business Research Company that provides neurostimulation device market statistics, including neurostimulation device industry global market size, regional shares, competitors with a neurostimulation device market share, detailed neurostimulation device market segments, market trends and opportunities, and any further data you may need to thrive in the neurostimulation device industry. This neurostimulation device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global neurostimulation devices market size will grow from $5.69 billion in 2022 to $6.28 billion in 2023 at a compound annual growth rate (CAGR) of 10.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurostimulation devices market size is expected to grow to $9.04 billion in 2027 at a CAGR of 9.5%. The rising geriatric population across the globe is driving the growth of the neurostimulation device market. An increasing number of the population is aging, and this geriatric population is falling prey to different neurobiological disorders. For instance, according to the World Health Organization, in 2020 1 billion people in the world were 65 years and above. The number is expected to reach 1.4 billion by 2030 and 2.1 billion by 2050. The high cost associated with the neurostimulation Devices will impede the growth of the market. For example, the average price of neuromodulation devices for chronic pain management range from $13920 to $17940, and the average price of neuromodulation devices for epilepsy ranges from $25420 to $25970. Although the device construction between neurostimulation and cardiac rhythm management devices is similar, neuromodulation generators are 67 percent more expensive than cardiac rhythm management devices. Minimally invasive treatments are being developed for the treatment of various neurological disorders. The neurostimulation devices are being innovated in a way to cause minimum invasion during neurological treatments. For example, Deep Brain Stimulation (DBS) is a minimally invasive surgical procedure to treat neurological symptoms of Parkinson’s disease, including tremors, rigidity, and movement control. DBS uses a neurostimulation device, similar to a heart pacemaker, to deliver electrical pulses to a very precise location in the brain circuits that influence Parkinson’s disease symptoms. The electrical pulses from the DBS device block the activity of these circuits so the rest of the brain can function more normally. USFDA strictly regulates the approval of medical devices depending on their class which is based on the risk associated with the device. There is relatively few class I neurological devices. The majority of the neurological devices are classified under Class II and Class III. Class II devices include neurostimulators, aneurysm clips, and blood clot retrievers. Examples of Class III devices are deep brain stimulators and medical devices for the treatment of brain tumors. Approval of class III medical devices is complicated and requires clinical trials. The time taken for the trials can be 36 months or more, depending on the extent of clinical trials and additional information that the FDA might request. Also, the European Union has recently taken steps to strengthen its regulatory approval process significantly, and this is expected to delay approvals in Europe. The delay in regulatory approvals and the high cost of interventional devices are the major challenges faced by the companies involved in the manufacture of neurological devices. In 2020, Medtronic, an Irish medical device company has acquired Stimgenics for an undisclosed amount. This acquisition is expected to boost the chronic pain treatment portfolio of Medtronic. Stimgenics is a private company based in Bloomington, that is pioneered in new spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed (DTM) spinal cord stimulation. After the completion of the acquisition, the new proprietary DTM SCS waveform will be available on the Medtronic Intellis Platform. Major players in the neurostimulation devices market are Medtronic, Cyberonics, Boston Scientific Corporation, St. Jude Medical, Nevro Corporation, Neuronetics Inc., NeuroPace Inc., NeuroSigma Inc., Cochlear Ltd., and NDI Medical. North America was the largest region in the global neurostimulation devices market in 2022. Asia-Pacific was the second-largest region in the neurostimulation devices market. The regions covered in global neurostimulation device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurostimulation devices market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The neurostimulation devices market consists of sales of spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global neurostimulation devices market is segmented - 1) By Product: Implantable Devices, External Devices 2) By Application: Pain Management, Epilepsy, Essential Tremor, Urinary and Fecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson's Disease 3) By End User: Hospitals, Rehabilitation Centers, Medical Clinic 4) By Implantable Devices: Cochlear Implants, Deep Brain Stimulation, Spinal Cord Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Gastric Electric Stimulation 5) By External Devices: Transcranial Magnetic Stimulation (TMS), Transcutaneous Electrical Nerve Stimulation (TENS)

Neurodegenerative disorder therapeutics refer to a medication or gene therapy to treat patients with neurodegenerative disorders therapeutically by directly rectifying pathogenic pathways, through neuroprotection, neurorestoration, and symptom control. The main drug types of neurodegenerative disorder therapeutics are n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various indications include Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, and other indications that ARE distributed through hospital pharmacy, retail pharmacy, and online pharmacy. The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global neurodegenerative disorder therapeutics market grew from $15.86 billion in 2022 to $17.14 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neurodegenerative disorder therapeutics market is expected to grow from $23.65 billion in 2027 at a CAGR of 8.4%. Increased prevalence of neurodegenerative among the global population contributes to the growth of the neurodegenerative disorder therapeutics market. The increase in the geriatric population attributes to the increased prevalence of neurodegenerative disorders. According to World Population Prospects, the number of people above 60 years of age will increase to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer’s Association, around 5.8 million Americans are suffering from Alzheimer’s disease, and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the aging population increases the demand for neurodegenerative disorder therapeutics thereby driving the market. High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently, very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer’s disease (AD) clinical trials, although there are 3558 in cancer trials. For instance, 12 of the 42 (28 percent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer’s disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate of 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer’s disease since 2013. The low rate of approval of neurodegenerative therapeutics hurts the market, hindering its growth of the market. Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non-government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market to increase their capabilities for research and development activities to develop new and more effective therapeutic solutions to treat neurodegenerative disorders. For instance, in July 2022, NRG Therapeutics, a UK-based drug discovery company focussed on therapeutic approaches, partnered with Domainex, a UK-based drug discovery service, to develop neurodegenerative disease treatment. For the treatment of Parkinson's disease, motor neurone disease (MND), and other incapacitating chronic neurodegenerative conditions, the firms would work together to develop novel small molecule disease-modifying medications. In January 2020, Biogen Inc., an American biotechnology company, paid $75 million for a novel clinical-stage asset, PF-05251749, as well as the applications from Pfizer.The acquisition of the asset is expected to strengthen Biogen’s existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases since PF-05251749 is a CNS-penetrant regulator that has the potential to treat behavioural and neurological symptoms across various psychiatric and neurological diseases. Pfizer Inc. is a multinational pharmaceutical company based in the USA. Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd., ACADIA Pharmaceuticals Inc., Lundeck A/S, Boehringer Ingeiheim International GmbH, Merck Serono, Orion Pharma Ltd., Mitsubishi Tanabe Pharma America, Allergan, GlaxoSmith Kline PLC., AbbVie, Eli lilly, Celgene, Neuro- Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation, AstraZeneca, Alector, Yumanity Therapeutics, Yangtze River Pharmaceutical Group, Chongqing Zein Pharmaceutical and Eisai. North America was the largest region in the global neurodegenerative disorder therapeutics market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global neurodegenerative disorder therapeutics market is segmented - 1) By Indication Type: Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types 2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types 3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Interventional neurology devices and equipment are used to treat neurovascular diseases such as aneurysms, arteriovenous malformations, cavernous malformations, and stroke. The main types of interventional neurology devices and equipment are aneurysm coiling and embolization devices, cerebrospinal fluid management devices, neuro thrombectomy devices, and support devices. The neuro thrombectomy devices are used to perform mechanical thrombus removal from intracranial arteries angiographically. The aneurysm coiling and embolization devices types are embolic coils, flow diversion devices, and liquid embolic devices. The angioplasty devices types are carotid artery stents and embolic protection systems. The support devices types are micro guidewires and microcatheters. The neurothrombectomy device types are clot retrieval devices, suction and aspiration devices, and snares. The various end-users are hospitals, neurology clinics, ambulatory care centres, and others. The interventional neurology devices and equipment market research report is one of a series of new reports from The Business Research Company that provides interventional neurology devices and equipment market statistics, including interventional neurology devices and equipment industry global market size, regional shares, competitors with a interventional neurology devices and equipment market share, detailed interventional neurology devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the interventional neurology devices and equipment industry. This interventional neurology devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global interventional neurology devices and equipment market size will grow from $1.99 billion in 2022 to $2.17 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interventional neurology devices and equipment market size is expected to grow to $2.97 billion in 2027 at a CAGR of 8.1%. An increase in the patient population with neurological disorders is driving the Interventional neurology devices market. Neural disorders like Alzheimer's disease, cerebrovascular diseases including stroke, migraine, and other headache disorders are on the rise. The rapid increase in the geriatric population, high-stress levels in young individuals, and head injuries due to accidents are the main reasons for neural disorders. For example, according to the Brain Aneurysm Foundation, it is estimated that in the United States, 6 million people suffer from unruptured brain aneurysms. Also, according to World Health Organization, more than 50 million have epilepsy and over 47 million have dementia. Hence, the rapid increase in the incidence of neurological disorders is slated to boost the market in the forecast period. Strict regulatory policies by the US FDA for the approval of Interventional Neurological Devices will hinder the interventional neurological devices market growth. FDA approves the devices based on the class of the devices. Most of the devices under Interventional Neurological Devices are classified under the class 3 devices. Class 3 devices are required to undergo a lot of approvals from the regulatory bodies which is a time-consuming process. For example, the approval for the class 3 devices may take more than 36 months, thereby increasing the overall cost of product development, impacting the market negatively. Stryker Inc.’s latest technological development Neuroform Atlas Stent System is expected to provide significant results to treat brain aneurysms with embolic coils. The introduction of such technologies would drive the interventional neurological device market in the future. The Atlas stent system provides great support during the coiling procedures and it has been designed s to provide the coil support and wall apposition needed to perform an effective stent-assisted coiling procedure. Neuroform Atlas has enhanced stent conformability, a low-profile delivery system, and high deployment accuracy even in distal anatomy making it the latest choice of the neuro-surgeons, thereby steering the market. The United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) presides over the regulation and approval of medical devices in the USA. Within CDRH, the Division of Neurological and Physical Medicine Devices reviews medical technologies that interface with the central and peripheral nervous system (neurotechnologies), including neuro-interventional medical devices that are used in the treatment of stroke. Also, the division of Neurological and Physical Medicine Devices (DNPMD) serves as the primary point of review at the FDA for regulatory submissions involving medical device neurotechnologies. Although the process of approval is strenuous and the time taken is too long, the devices approved by FDA have had a major impact on the markets and the products approved by FDA are successful. FDA has been actively approving devices in the interventional neurosurgery device division which has boosted the market’s growth. For example, approval of Stryker’s Neuroform Atlas Stent System, De Novo clearance for Nerivio Migra, and Pipeline Flex embolization by Medtronic are the recent approvals made by FDA which enhances the market’s growth. Major players in the interventional neurology devices and equipment market are Medtronic, Stryker, Terumo Corporation, Penumbra, COVIDien, Abbott, Merit Medical Systems, Johnson & Johnson Services Inc., W. L. Gore & Associates, and Bayer AG. North America was the largest region in the global interventional neurology devices and equipment market in 2022. Asia-Pacific was the second-largest region in the interventional neurology devices and equipment market. The regions covered in the global interventional neurology devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional neurology devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The interventional neurology devices and equipment market consists of sales of instruments such as carotid artery stents, embolic protection systems, micro guide wires, and micro catheters. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global interventional neurology devices and equipment market is segmented - 1) By Type: Aneurysm Coiling & Embolization Devices, Cerebrospinal Fluid Management Devices, Neurothrombectomy Devices, Support Devices 2) By End-User: Hospitals, Neurology clinics, Ambulatory care centers and others 3) Aneurysm Coiling & Embolization Devices By Type: Embolic coils, Flow diversion devices, Liquid embolic devices 4) Angioplasty Devices by Type: Carotid artery stents, Embolic protection systems 5) Support Devices By Type, Micro guide wires, Micro catheters 6) Neurothrombectomy Devices By Type: CLOT retrieval devices, Suction and aspiration devices, Snares

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

Neuroprosthetics is the study of neuroprostheses and brain-machine interfaces. Neuroprosthetic devices substitute the cognitive or sensory functions that have been impaired due to nervous system disorders. They encompass various artificial devices or systems that can enhance the output or input of a neural system. The major purpose of neuroprosthetics is to allow brain-injured patients to participate in day-to-day life and improve their quality of life. The main types of neuroprosthetics are motor neuroprosthetics, auditory neuroprosthetics/ cochlear implants, visual neuroprosthetics/ retinal implants, and cognitive neuroprosthetics. As an orthosis, motor neuroprosthesis (MN) includes electrical stimulation of brain areas to promote the activities and involvement of persons who have had a stroke in their natural environment. The various techniques used are spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, sacral nerve stimulation, and transcranial magnetic stimulation which are applied in various disorders such as motor neuron disorders, physiological disorders, and cognitive disorders. The neuroprosthetics market research report is one of a series of new reports from The Business Research Company that provides neuroprosthetics market statistics, including neuroprosthetics industry global market size, regional shares, competitors with a neuroprosthetics market share, detailed neuroprosthetics market segments, market trends and opportunities, and any further data you may need to thrive in the neuroprosthetics industry. This neuroprosthetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global neuroprosthetics market size grew from $8.09 billion in 2022 to $9.24 billion in 2023 at a compound annual growth rate (CAGR) of 14.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neuroprosthetics market size is expected to grow to $16.03 billion in 2027 at a CAGR of 14.7%. The rising patient population suffering from neurological disorders and nerve injuries is expected to propel the growth of the neuroprosthetics market. Neurological disorders are referred to as disorders that affect the brain and the nerves present in the human body and the spinal cord. Nerve injuries are the damages caused to nerves due to pressure, cuts, or stretching during an accident or any unpredicted event. Neuroprosthetics help patients with such disorders and injuries to restore their lost motor and sensory functions. For instance, according to the world Health Oganization (WHO), a Switzerland-based health agency of the united nations, in 2022, 50 million people globally were suffering from epilepsy, nearly 80% of them were living in low and middle-income countries. Therefore, the growing patient population suffering from neurological disorders and nerve injuries is driving the growth of the neuroprosthetics market. Technological advancements are shaping the neuroprosthetics market. Technological advancement is defined as a discovery of knowledge that advances technology to provide an enhanced product to the customers. For instance, in July 2021, the University of California San Francisco Parnassus Campus (UCSF), a US-based academic medical center, developed Speech Neuroprosthesis. The new achievement was developed by researchers of UCSF, which enabled paralysis patients to directly translate the signals from their brain to the vocal tract, which appear as text on the screen. The technology used is Brain-Computer Interface Restoration of Arm and Voice which uses human vocabulary with advanced computer algorithms that are used to recognize brain activity. In February 2021, Flow Neuroscience, a Sweden-based developer of a brain stimulation device, acquired Halo Neuroscience, for an undisclosed amount. With this acquisition, Flow Neuroscience aims at providing more personalized solutions related to brain disorders. Halo Neuroscience is a US-based developer of brain stimulators that develops muscle memory faster and develops and designs neuroprosthetics. Major players in the neuroprosthetics market are Medtronic plc, Cochlear Ltd., Abbott Laboratories, Boston Scientific, LivaNova PLC., Second Sight Medical Products Inc., MED-EL, Retina Implant AG, Sonova, Neuropace, NDI Medical LLC, Demant AS, Oticon, St. Jude Medical Inc. and Biomet Inc. North America was the largest region in the neuroprosthetics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroprosthetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the neuroprosthetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The neuroprosthetics market includes revenues earned by entities by peripheral nerve, brain-computer interface, electro stimulation, neurostimulation, cochlear implant, stimulation, femoral nerve and carbon nanotube. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global neuroprosthetics market is segmented - 1) By Type: Motor Neuroprosthetics, Auditory Neuroprosthetics/ Cochlear implants, Visual Neuroprosthetics/ Retinal implants, Cognitive Neuroprosthetics 2) By Technique: Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Transcranial Magnetic Stimulation 3) By Application: Motor Neuron Disorders, Physiological Disorders, Cognitive Disorders

Brain and neuroimaging devices are medical devices used to capture the structure, function, or pharmacology of the brain and locate areas affected by neurological disorders. The main imaging types of brain and neuroimaging devices are functional magnetic resonance imaging (fMRI), computed tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG), and others. Positron emission tomography (PET) is a type of imaging technique that measures the metabolic activity of the cells of body tissues using radioactive substances. The various applications of brain and neuroimaging devices are Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and other applications that are used in hospitals, diagnostic centers, and ambulatory surgical centers. The brain and neuroimaging devices market research report is one of a series of new reports from The Business Research Company that provides brain and neuroimaging devices market statistics, including brain and neuroimaging devices industry global market size, regional shares, competitors with a brain and neuroimaging devices market share, detailed brain and neuroimaging devices market segments, market trends and opportunities, and any further data you may need to thrive in the brain and neuroimaging devices industry. This brain and neuroimaging devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global brain and neuroimaging devices market size will grow from $35.49 billion in 2022 to $37.53 billion in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The brain and neuroimaging devices market size is expected to grow from $47.15 billion in 2027 at a CAGR of 5.9%. An increase in the incidence of neurological disorders is expected to drive the market. According to a report by the European Academy of Neurology, 1 in 3 people in 2022 are affected by a neurological disease and the number of deaths due to neurological disorders increased by almost 40% in the last 30 years. Brain and neuroimaging devices are used to diagnose neurological disorders increasing the survival rate and management of the disease. This increasing incidence rate is expected to drive the brain and neuroimaging devices market. The high cost of imaging devices is anticipated to hamper the market for brain and neuroimaging devices. Neurological and cognitive psychology research and design brain-computer interfaces require high-end machines such as Electroencephalography (EEG), Positron Emission Tomography (PET), Functional Magnetic Resonance Imaging (fMRI) among others. These are high-cost devices, for instance, the new 64-slice CT scanners range between $500,000 and $700,000, cost of a PETCT scanner ranges from $225,000 to $750,000, which is not affordable for all hospitals and labs, mainly in developing countries. Thus, the high cost of imaging devices hampers the buying capacity of hospitals and diagnostic labs, hampering the brain and neuroimaging devices market. Companies and researchers are focusing on developing portable brain scanners that are expected to revolutionize brain imaging by lowering the cost of devices, making them affordable and accessible to all. EMVision Medical Devices and researchers at Queensland University have developed a portable brain scanner technology that enables brain scanning to be performed at almost any location. Researchers at University College London have developed a portable MEG brain scanner that is lightweight, worn like just a helmet but can measure brain activity even as people make natural movements, providing improved imaging opportunities for patients with disorders that cause unprompted body movements, such as epilepsy. Major players in the brain and neuroimaging devices market are GE, Siemens, Philips, Canon, Hitachi Medical Systems, Medtronic PLC., EB Neuro S.p.A., Neurosoft, MinFound Medical Systems Co. Ltd., and Elekta. Western Europe was the largest region in the brain and neuroimaging devices market in 2022. North America was the second largest region in the global brain and neuroimaging devices market report. Africa. was the smallest region in the brain and neuroimaging devices market. The regions covered in the global brain and neuroimaging devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the brain and neuroimaging devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The brain and neuroimaging devices market consists of sales of imaging equipment for brain and nerves such as functional magnetic resonance imaging, computed tomography, positron emission tomography (pet), electroencephalography, magnetoencephalography, and others. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global brain and neuroimaging devices market is segmented - 1) By Imaging Type: Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types 2) By End-user: Hospitals, Diagnostic Centres, Ambulatory Surgical Centres 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications